This is very >> It's bad, right. >> It's hard. Yeah.>> That's what it's like to be old. And for far too long, we've [music] ignored it or accepted it as natural. And I reject the idea that aging just because it's natural is acceptable.Dying at 80 is not inevitable. Absolutely, that can be changed. So, if you're skeptical, I am a Harvard professor who has been studying aging, longevity, and age reversal for 30 years.And I've seen enough from my lab showing that we can literally now reverse the aging process. ...

The Dog Aging Project is working to help dogs live longer, healthier lives. The research results may help humans age well, too. "60 Minutes" is the most successful television broadcast in history. Offering hard-hitting investigative reports, interviews, feature segments and profiles of people in the news, the broadcast began in 1968 and is still a hit, over 50 seasons later, regularly making Nielsen's Top 10. Subscribe to the "60 Minutes" YouTube channel: https://youtube.com/60minutes Watch full episodes: h ...

Two fields in particular draw attention when we look at Abbott. The company’s FreeStyle Libre product is a leader in the continuous glucose monitoring (CGM) market, a vital technology in controlling and managing diabetes. Abbott’s product boasts that it is the leading CGM brand in the US. Abbott’s cardiovascular products include devices to manage such conditions as heart failure, irregular heartbeat, and mitral regurgitation.The first company we’ll look at, Abbott Laboratories, was founded in 1888 – and has ...

What's going on, guys? Today, we've got a very special treat. I have a conversation with Peter Diamandis. Peter is one of the forwardthinking leaders when it comes to artificial intelligence, longevity, technology in general. He's one of my favorite people to talk about innovation and where the world is headed. Peter's got a brand new book called We Are as Gods. That's coming out in April. And he's here to break down how to prepare for the Age of Abundance and what you should be thinking in artificial intel ...

The drugs are being sought out by healthy people in the hope that they will help preserve that health for longer, and even extend life. Does the science bear that out? https://t.co/UvbQJAMJgB ...

Boosters say they will do everything from aiding strength, recovery and longevity https://t.co/NzdyMQxB67 ...

Now for the next two minutes, I would like you to lay back on your seat and listen to my voice. Please close your eyes and focus on your breathing. You inhale from your nose. You exhale from your mouth.You're more focused, relaxed once again. Inhale. Exhale.Feel more energetic. Once more. Inhale.Exhale. And now that you are focused, I want you to think what you did yesterday. See it like a movie in your mind.You got out of bed. You woke up. You had your breakfast.You went to work. You had your lunch. You ha ...

What I want to do is really talk about three I think prevalent fictions in the field right now. Certainly if you consume at all sort of longevity influencer stuff on the internet you will have heard these and unfortunately we see some of these fictions showing up in the scientific literature even um which I view as problematic. Um, and then I want to talk about three of the core facts in the in the field that I think really set the foundation for where we're at, the trajectory going forward, and and why sci ...

Financial Data and Key Metrics Changes - In Q4 2025, revenue was $33.8 million, a 16% year-over-year increase, with net income of $4.1 million [10] - For the full year 2025, net revenue reached $129.4 million, representing a 30% growth year-over-year, and net income was $17.4 million [10][38] - The company ended the year with $64.8 million in cash and no debt, indicating strong financial stability [10][43] Business Line Data and Key Metrics Changes - Revenue from the Tru Niagen product line grew by 21% to $27.5 million, driven primarily by e-commerce sales of $20.2 million, which increased by 17% [40] - Niagen ingredient revenue was $5.6 million, up 5% year-over-year, with food-grade sales at $4.7 million and pharma-grade sales at $900,000 [40] - Revenue from B2B distribution partners totaled $7.3 million, supported by strategic partnerships [41] Market Data and Key Metrics Changes - The company is expanding its presence in over 1,200 health clinics and plans to launch at-home Niagen Plus injection kits through a telehealth platform [15] - The company anticipates continued growth in the Asia-Pacific markets and selective retail channels [66] Company Strategy and Development Direction - The company aims to focus on NAD science and intellectual property while exiting non-core activities, as evidenced by the sale of the ChromaDex Reference Standards business [21][45] - Plans include expanding into the beauty cosmetics market and launching new products, including topical products featuring Niagen [16][66] - The company is committed to maintaining its leadership in NAD science and enhancing its product offerings through strategic R&D investments [20][48] Management's Comments on Operating Environment and Future Outlook - Management acknowledged increased competition in the NAD space but emphasized the company's strong foundation and expertise [11] - The company expects to achieve 10%-15% growth in net sales for 2026, with a slight improvement in gross margin [45][46] - Management expressed confidence in the company's ability to deliver value to stakeholders and maintain its market position [48] Other Important Information - The company secured a patent for intravenous and injectable formulations of NR, indicating potential for new product development [15] - Ongoing litigation against the FDA regarding NMN products is expected to have minimal impact on legal expenses [76] Q&A Session Summary Question: Discussion on injections and telehealth platform - Management confirmed that initially, there will be one SKU for injections, targeting the biohacker community and those interested in longevity interventions [53] Question: Guidance for 2026 - Management indicated that the guidance is conservative, reflecting a cautious approach to revenue projections [58] Question: Growth drivers for 2026 - Management expects growth from existing products, new distribution channels, and increased brand awareness [66] Question: Lawsuit against the FDA - Management believes the case will likely result in a summary judgment and is optimistic about a favorable outcome [76] Question: Share repurchase strategy - Management plans to utilize the remaining $9.75 million of the buyback program, viewing it as a good investment at current prices [79]

Summary of Ventas Conference Call Company Overview - **Company**: Ventas, an S&P 500 company focused on senior housing and the aging population trend [3][4] - **Key Participants**: - Debra Cafaro - Chairman and CEO - Justin Hutchens - EVP, Senior Housing, and CIO - BJ Grant - SVP of Investor Relations [1][2] Core Industry Insights - **Industry Focus**: Senior housing, driven by the aging population and longevity trends [3] - **Market Dynamics**: - Strong demand due to the aging baby boomer population, with 2 million people turning 80 in 2026 [5][6] - Supply of senior housing is at historic lows, with only 2,000 units started in Q4, leading to a favorable supply-demand imbalance [6][7] Financial Performance and Growth - **Historical Returns**: Ventas has delivered 19% annual returns since 2000 [3] - **Occupancy Rates**: Current U.S. occupancy is at 86%, with expectations for further growth [7][11] - **NOI Growth**: Anticipated double-digit NOI growth for five consecutive years, driven by strategic positioning and market demand [16][17] Strategic Initiatives - **Operational Enhancements**: - Implementation of data analytics and technology to improve operational efficiency and decision-making [8][19] - Transitioning from triple net lease structures to a more operationally focused model, enhancing revenue potential [16][29] - **Acquisition Strategy**: - Over $5 billion in senior housing investments in the past five quarters, with a focus on acquiring well-positioned assets [8][25] - Strong competitive position due to financial strength and operational focus, leading to repeat business with existing operators [26][28] Market Positioning - **Demographic Targeting**: Focus on markets with strong aging demographics and affordability metrics, ensuring residents can afford services [35][36] - **Product Mix**: Balanced portfolio of independent living and assisted living facilities, catering to different resident needs [37][38] Future Outlook - **Growth Projections**: Continued focus on capitalizing on macro trends, with expectations for sustained NOI growth and shareholder value creation over the next decade [4][41] - **Labor Market**: Improved labor market conditions, with competitive wages and retention strategies in place to ensure high-quality service delivery [48][50] Additional Considerations - **Affordability Metrics**: Residents can afford 14-21 years of stay based on median income, indicating strong market demand [35][36] - **Operational Insights Platform**: A key tool for enhancing operational performance and driving revenue growth through data-driven decision-making [23][24] This summary encapsulates the key points discussed during the Ventas conference call, highlighting the company's strategic focus, market dynamics, and future growth potential.